Erratum to:Tetrabenazine as anti-chorea therapy in Huntington Disease: an open-label continuation study
© Frank and Huntington Study Group/TETRA-HD Investigators; licensee BioMed Central Ltd. 2011
Received: 3 February 2011
Accepted: 4 February 2011
Published: 4 February 2011
The Research article to this article has been published in BMC Neurology 2009 9:62
After publication of this work , we became aware of a typographical error. The term dysphagia inadvertently replaced the term dysarthria in two instances. Dysarthria was statistically significantly worsened at week 80 compared to baseline, whereas there was only a statistical trend (p = 0.10) for dysphagia at week 80 compared to baseline. Dysphagia continues to be an issue in patients with Huntington Disease and was reported as an adverse event in this study. Therefore, clinicians who prescribe tetrabenazine should still monitor their patients for worsening swallowing, but the worsening was not statistically different in those who completed this trial. No further studies of tetrabenazine in Huntington Disease have been completed since the publication of this study.
Dysarthria should be replaced for dysphagia in two places and the manuscript should read as follows:
Abstract, page 1:
Results: Parkinsonism and dysarthria scores were significantly increased at week 80 compared to baseline.
Discussion, page 8:
Although parkinsonism and dysarthria were increased in subjects at week 80, this finding was likely a result of the natural progression of disease.
The other uses of the terms dysarthria and dysphagia in the manuscript are correct. We regret the error and any inconvenince it may have caused.
- Frank S, Huntington Study Group/TETRA-HD Investigators: Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study. BMC Neurol. 2009, 9: 62-10.1186/1471-2377-9-62.PubMed CentralView ArticlePubMed
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2377/11/18/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.